

**Mean Platelet Volume Levels in Pregnant Women having Thalassemia Minors**

**Dilek Benk Silfeler<sup>1</sup>, Arif Gungoren<sup>1</sup>, Kenan Dolapcioglu<sup>1</sup>, Raziye Keskin Kurt<sup>1</sup>,  
Atilla Karateke<sup>2</sup>, Ali Ulvi Hakverdi<sup>1</sup>, Secil Gunher Arica<sup>3</sup>, Ali Baloglu<sup>1</sup>**

<sup>1</sup> M.D., Mustafa Kemal University, Faculty of Medicine, Department of Obstetrics and Gynecology, Hatay, Turkey.

<sup>2</sup> M.D., Hatay State Hospital, Obstetrics and Gynecology clinic, Hatay, Turkey.

<sup>3</sup> M.D., Mustafa Kemal University, Faculty of Medicine, Department of Family Medicine, Hatay, Turkey.

**Abstract**

**Aim:** One of the designators of platelet functions is mean platelet volume. We aimed to compare mean platelet volume levels between the thalassemi minors pregnant women and normal pregnant women.

**Methods:** Files of 46 thalassemi minors pregnant women and 52 pregnant women without thalassemia minors or any other hematologic and metabolic disorders who applied to obstetrics and gynecology clinic were retrospectively evaluated. Groups were statistically compared regarding mean platelet volume values.

**Results:** There was no significant difference between the groups in terms of mean platelet volume and numbers of platelet ( $p>0.05$ ). Mean platelet volume and platelet values in thalassemia minors pregnant have been relatively high in comparison to the control group but it didn't reach statistical significance.

**Conclusion:** According to our study results, there is no a clear association between thalassemia minors status and mean platelet volume.

**Key Words:** Mean Platelet Volume, Thalassemia minors, Pregnancy

**Corresponding Author:** Dilek Benk Silfeler ,

Mustafa Kemal University, Faculty of Medicine, Department of Obstetrics and Gynecology, Hatay, Turkey

E-mail: drsilfeler@yahoo.com

**Introduction**

Beta thalassemia formed as a result of an inherited mutation in the beta globin gene is a disease caused by the construction of defective hemoglobin. Although approximately 200 gene mutations may cause the disease, common clinical

phenotype is observed (1). The most significant feature of the disease is anemia and the severity of anemia change depending on the heterozygous and homozygous types (2,3,4). The presence of mutation in the unique chromosome is explained as beta thalassemia minor (5,6). Majority of thalassemia minors are

asymptomatic. In addition, it can be encountered with the signs of mild anemia (7,8). This anemia displays hypochromic microcytic character(6). Based on the World Health Organization data, the carriage rate in our country is 2.1% while this rate is 5.1% worldwide(3,4).

In the previous studies, an association with the coronary artery diseases and beta thalassemia minor has been established and development of acute myocardial infarction in some patients have been displayed (1,9,10,11). In spite of the studies, cause and effect relationship between thalassemia minor and coronary artery diseases has not been clearly revealed (1).

Platelet size is associated with the platelet function and activation (12). Hemostatic functions of big platelets are more (13). For this reason, mean platelet volume (MPV) is an important indicator for the activation of platelet, and its highness is an important finding for atherosclerosis (14).

In this study, we aimed to investigate association between thalassemia minors pregnant and MPV values since there is a relation between increased risk of ischemic heart disease and beta thalassemia, and also increased MPV values in atherosclerosis.

#### **Material and Methods**

This study was carried out with the approval of ethical committee of Mustafa Kemal University(numbered of 13). Thalassemi carrier pregnant and normal pregnant without thalassemia minors or systemic disorders that applied to obstetrics and gynecology outpatient clinic were retrospectively evaluated. MPV is stable during pregnancy (15-17). However, MPV is bigger than 11 fL in 28 week gestation is a risk factor for preeclampsia. For this reason, pregnant having preeclampsia were excluded in this study. Basal characteristics

of women reached from files. MPV and platelet numbers in the complete blood count obtained during the routine follow-up were recorded. Pregnants whose platelet numbers are below 150.000/  $\mu$ L and above 400.000/  $\mu$ L were excluded in the study.

Statistical evaluation was made using SPSS 15.0 program. T test was used for the comparison of averages. Comparison of the fields was made with the Mann-Whitney U-test. Pearson correlation test was used while monitoring the correlation between parametric values. Spearman correlation test was used in order to monitor the correlation of non-parametric results. chi-square test was used in analyzing the two categorical variable.

#### **Results**

Files of 98 pregnant between 18-25 pregnancy week were scanned. 52 normal pregnant having no hematologic or systemic disease that came for routine pregnancy follow-up were included as the control group (Group I). 56 pregnant women that were diagnosed as thalassemia minor were included as the study group (Group II). No statistical differences in terms of age, pregnancy week, height, weight, systolic and diastolic blood pressure were found.

A meaningful difference between Group I and Group II was not found in terms of mean MPV and mean platelet values( $p>0.05$ ). Although mean MPV and platelet values in Group II were higher than Group I, the difference did not reach statistical significance.

Table 1. Comparison of hematological parameters among the groups

Parameter	Group 1 (n:52)	Group 2 (n:46)	Group comparisons (p value)*
MPV (fL)	8.2±0.9 (6.4-11.1)	8.5±1.4 (5.7-13.1)	P>0.05 (p:0.188)
PLT (×103/μL)	256±57 (153-441)	262±57 (151-410)	p>0.05 (p:0.626)

values are given as mean ± SD

\*p&lt;0.05 is significant

## Discussion

Change in platelet count were observed in many disease. Many diseases inducing these changes could cause defects in the volume and function of the platelets. Platelet volumes in the circulation display a heterogenic spread. For this reason, mean platelet volume (MPV) is taken into consideration while evaluating the platelet volume (18). Generally, as the number of platelet decreases, MPV increases (19). In fact, it would be more accurate to say that MPV increases as the renewal speed of platelet increases (20).

Big platelets are more reactive, thus produce more prothrombotic factors and pile up easier (21, 22). So, MPV is accepted as the platelet activation indicator alone (15, 23). Increased MPV in idiopathic thrombocytopenic purpura (ITP) might demonstrate increase in the platelet destruction based on preeclampsia or sepsis. Decreased MPV might indicate hypersplenism or hypoplastic platelet production. Increased MPV values without thrombocytopenia is seen in chronic myeloid leukemia and heterozygotes

thalassemia. MPV values decreases in chronic renal failure and uremic bleeding diathesis. There are small platelets and increased heterogeneity in megaloblastic anemia (16).

Sarneke and his colleagues proved that anemia is an important risk factor for coronary artery disease (24). Shahriari proved that decreased hemoglobin levels in thalassemic patients is associated with ischemic heart disease (25). In the study made by Hashemi and his colleagues, no meaningful association between thalassemia minor and coronary artery disease was located (1). During acute myocardial infarction, we know that MPV increases and increased MPV is an independent risk factor for acute myocardial infarction (17, 26). In our study, although we were unable to locate any statistically meaningful association between thalassemic minor pregnant and control group in terms of MPV levels, we found that PLT and MPV values were higher in thalassemic minor group. We think that this situation is arisen from the limited number of the cases.

Several mechanisms have been put forward in order to explain the association among the

cardiovascular diseases in thalassemic minor patients. Some of these are increased cholesterol and LDL level, decreased blood viscosity based on decreased hemoglobin and hematocrit values and presence of hypertension in a small degree (24, 27, 28). In our study, there was no meaningful difference between two groups in terms of hypertension.

**Cerebrovascular accident:** Cerebrovascular diseases caused by hypertension are the most frequent neurological diseases in old people. Atherosclerotic lesions in the neck cause transient ischemic attacks, thrombotic or embolic strokes. After 1 month following the stroke, decreased platelet number and increased PV are found. This is up to increase of platelets consumption in infarct field (15, 17). There are publications showing the relationship between beta thalassemia minor and oxidative damage(4, 29).

Since the incidence of thalassemia minor in our country is high, many carrier pregnant women are examined in our clinic. Thalassemia minors status is associated with lots of diseases. Even though we were unable to find a relationship between thalassemia minors status and MPV in pregnant women, it is obvious that large scaled prospective studies are needed.

**Conflict of Interest: None.**

### References

1. Hashemi M, Shirzadi E, Talaei Z, Moghadas L, Shaygannia et al. Effect of heterozygous  $\beta$ -thalassaemia trait on coronary atherosclerosis via coronary artery disease risk factors: a preliminary study. *Cardiovascular Journal Of Africa* 2007;18(3):165-8
2. Selek S, Aslan M, Horoz M, Gur M, Erel O. Oxidative status and serum PON1 activity in beta-thalassemia minor. *Clin Biochem.* 2007; 40: 287-291.
3. Yaprak I. Beta Talasemi Tanı ve Tedavisinde Guncel Yaklaşımlar. *STED* 2004;13:58-9.
4. Kızılar AR, Aydemir B, Kurtoğlu E, Uğur A. Beta Talasemi Minörlü Hastalarda Eser Element ve Oksidatif Hasar İlişkisi. *Fırat Tıp Dergisi* 2009;14(1):28-32
5. Sadeghi-Bojd S, Hashemi M, Naderi M, Shikhani S. Kidney Function Tests in Children with Beta-Thalassemia Minor in Zahedan, Southeast of Iran *Iranian Journal of Kidney* 2011;5(3):201-3
6. Clarke GM, Higgins TN. Laboratory investigation of hemoglobinopathies and thalassemias: review and update. *Clin Chem.* 2000;46:1284-90.
7. Prabahar MR, Jain M, Chandrasekaran V, Indhumathi E, Soundararajan P. Renal Tubular Dysfunction with Nephrocalcinosis in a Patient with Beta Thalassemia Minor. *Saudi J Kidney Dis Transpl.* 2008;19(6):964-8.
8. Forget BG. Thalassemia syndromes. In: *Hematology: Basic principles and practice*, 3rd Edition, Hoffman, R, Benz, Jr EJ, Shattil, SJ, et al, (Eds), Churchill Livingstone, New York 2000.p.485
9. Baserga A, Barraï I, Bonomo L, Carcassi U, Coppo M, Castaldi G, et al. Clinical aspects of beta-thalassaemia minor. *Panminer Med* 1982;24(4):275-7.
10. Crowley JP, Sheth S, Capone RJ, Schilling RF. A paucity of thalassemia trait in Italian men with myocardial infarction. *Acta Haematol* 1987;78:249-51.
11. Wang CH, Schilling RF. Myocardial infarction and thalassemia trait: an example of heterozygote advantage. *Am J Hematol* 1995; 49(1):73-5.

12. Martin JF, Trowbridge EA, Salmon G et al The biological significance of platelet volume: its relationship to bleeding time, thromboxane B<sub>2</sub> production and megakaryocyte nuclear DNA concentration. *Thromb Res* 1983;32:443–60
13. Thompson CB, Eaton KA, Princiotta SM et al Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. *Br J Haematol* 1982;50:509–19
14. Coban E, Adanir H. Platelet activation in patients with familial Mediterranean fever. *Platelets* .2008; 19:405–8
15. Bancroft AJ, Abel W, et al. Mean trombosit volume is a useful parameter: a reproducible routine method using a modified Coulter Thrombocytometer. *Trombosit* 2000;11:379-87.
16. Dow RB. The Clinical and laboratory utility of trombosit volume parameters. *Jnl Medical Science* 1994;15:1-15.
17. Bath PM, Butterworth RJ. Trombosit size: measurement, physiology and vascular disease. *Blood Coagulation and Fibrinolysis* 1996;7:157-61.
18. Paulus JM, Bury J, Grosdent JC. Control of platelet territory development in megakaryocytes. *Blood Cells* 1979;5(1):59-88.
19. Cole JL, Marzec UM, Gunthel CJ, Karpatkin S, Worford L, Sundell IB et al. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. *Blood* 1998;91(9):3239-46.
20. Silfeler I, Dorum BA, Silfeler DB, Arica SG. Comparison of Levels in Preterm and Term Neonates Mean Platelet *JCAM* 2013;4(4):259-61
21. Akarsu S, Kurt ANÇ, Kurt A, Varol İ, Şen Y. Thrombocyte volume parameters in different disease groups. *Turk Arch Ped.* 2006;41:208-13
22. Thompson CB, Jakubowski JA, et al. Trombosit size as a determinant of trombosit function. *J Lab Clin Med* 1983;101:205-13.
23. Cox D. Methods for Monitoring Trombosit Function. *Am Heart J* 1998;135:16069.
24. Sarnak MJ, Tighiouart H, Manjunath G, Macleod B, Griffith J, Salem D, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk In Communities (ARIC) study. *J Am Coll Cardiol* 2002; 40(1): 27–33.
25. Shahriari M, Zibae-Nejad MJ, Bokae HR. Is minor thalassemia a protective factor against myocardial infarction. *Iran J Med Sci* 1998;23(3, 4): 134.
26. Şenaran H, İleri M, Altınbaş A, et al. Thrombopoietin and mean trombosit volume in coronary artery disease. *Clin Cardiol* 2001;24:405-8.
27. Deiana L, Garuti R, Pes GM, Carru C, Errigo A, Rolleri M, et al. Influence of beta(0)-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia. *Arterioscler Thromb Vasc Biol* 2000;20(1): 236–43.
28. Namazi MR. Minor thalassemia as a protective factor against cerebrovascular cerebrovascular accidents. *Med Hypoth* 2002;59(3):361–2.
29. Scott MD. H<sub>2</sub>O<sub>2</sub> injury in beta thalassemic erythrocytes: protective role of catalase and the prooxidant effects of GSH. *Free Radic Biol Med.* 2006; 40:1264-72.